Diasome Overview
- Year Founded
-
2004
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
2ndary - Private
- Investors
-
2
Diasome General Information
Description
Developer of novel and cell-targeted therapies designed to treat diabetes, obesity, and other metabolic conditions. The company's therapies leverage technology, an insulin additive, to lessen the instances of high and low blood sugar levels in people with diabetes, enabling patients to get novel proprietary liver-targeted insulins for both Type one and Type two diabetes easily.
Contact Information
Website
www.diasome.comCorporate Office
- 10000 Cedar Avenue
- Suite 6
- Cleveland, OH 44106
- United States
Corporate Office
- 10000 Cedar Avenue
- Suite 6
- Cleveland, OH 44106
- United States
Diasome Timeline
Diasome Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Secondary Transaction - Private | Completed | Clinical Trials - Phase 2 | ||||
| 9. Later Stage VC | 14-Aug-2024 | Completed | Clinical Trials - Phase 2 | |||
| 8. Later Stage VC (Series C) | 30-Jun-2023 | Completed | Clinical Trials - Phase 2 | |||
| 7. Later Stage VC (Series B) | 08-Sep-2022 | Completed | Clinical Trials - Phase 2 | |||
| 6. Secondary Transaction - Private | Completed | Clinical Trials - Phase 1 | ||||
| 5. Later Stage VC (Series B2) | 26-Oct-2018 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC (Series A) | 05-Jul-2017 | Completed | Clinical Trials - Phase 1 | |||
| 3. Secondary Transaction - Private | Completed | Pre-Clinical Trials | ||||
| 2. Later Stage VC (Series B) | 10-Apr-2009 | $13.2M | $16.4M | Completed | Pre-Clinical Trials | |
| 1. Later Stage VC (Series A) | $3.2M | $3.2M | Completed | Startup |
Diasome Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series B | 11,382,112 | $0.000100 | 8% | $1.23 | $1.23 | 1x | $1.23 | 13.07% |
| Series A | 20,852,974 | $0.000100 | 8% | $1.23 | $1.23 | 1x | $1.23 | 23.94% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Diasome Patents
Diasome Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026187938-A1 | Compositions for delivery of therapeutic drugs and methods using same | Pending | 04-Mar-2025 | ||
| WO-2026161629-A1 | Compositions and methods for modulating peripheral and hepatic lipid metabolism in hdv-based insulin therapy | Pending | 24-Jan-2025 | ||
| WO-2026107515-A1 | Incretin hormone compositions and methods using same | Pending | 18-Nov-2024 | ||
| US-12758504-B2 | Compositions comprising lipid-based nanoparticles for treating diabetes mellitus | Active | 05-Jan-2018 | ||
| US-20240108585-A1 | Compositions comprising lipid-based nanoparticles for treating diabetes mellitus | Active | 05-Jan-2018 | A61K9/5123 |
Diasome Signals
Diasome Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Eli Lilly and Company Foundation | Limited Partner | Minority | ||
| T1D Fund | Venture Capital | Minority |
Diasome FAQs
-
When was Diasome founded?
Diasome was founded in 2004.
-
Where is Diasome headquartered?
Diasome is headquartered in Cleveland, OH.
-
What is the size of Diasome?
Diasome has 10 total employees.
-
What industry is Diasome in?
Diasome’s primary industry is Drug Discovery.
-
Is Diasome a private or public company?
Diasome is a Private company.
-
What is Diasome’s current revenue?
The current revenue for Diasome is .
-
How much funding has Diasome raised over time?
Diasome has raised $89.7M.
-
Who are Diasome’s investors?
Eli Lilly and Company Foundation and T1D Fund have invested in Diasome.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process